Friday 29 May 2015, Amsterdam
A new report, now available on ASDReports, forecasts the overall world market for human antibacterial treatments will reach $43.2bn in 2019. That revenue prediction and others appear in Antibacterial Drugs: World Industry and Market Prospects 2015-2025, published in April 2015.
From 2015, new therapies and high medical needs encourage investments, developments, wider treatment and higher sales from bacteria-treating medicines. The new study discusses commercial potentials of human antibiotics and their producers. That investigation gives multilevel revenue forecasting to 2025. It shows predictions and discussions planners, organisers and leaders need.The report is a business information publisher and consultancy in London, UK. It produces research, data and analysis to help organisations understand markets and their potentials.
The report predicts the antibacterial drug market will experience slow growth in the first half of its forecast period, 2015-2025, owing to high use of generic drugs (generics), coupled with a limited R&D pipeline of new therapies. Increasing resistance to current antibiotics is also limiting the treatment choice for healthcare providers.
Sandra Wenas, a pharmaceutical industry analyst, said: “The antibacterial drug market has experienced stagnant growth in recent years due to lack of new entrants and genericisation. Efforts to regulate consumption and the rising prevalence of treatment-resistant bacteria in emerging and developed national markets affect overall antibacterial drug sales.
“Current leading drugs will lose patent exclusivity from 2015 to 2025, opening opportunities for generics manufacturers, eroding the market size with low-cost options. The overall antibacterial therapies market, however, will expand with a CAGR of 2.2% from 2019-2025, we predict. The uptake of new drugs launched within the second half of our forecast period will stimulate that revenue growth. That industry segment holds challenges and potential for commercial success and benefiting patients. It remains a core pharmaceuticals market.
“And there is growing need for more novel antibacterial medicines, especially drugs to treat Gram-negative infections where unmet clinical needs exist worldwide. There progress occurs, as our study explains, highlighting developments and their potentials.”
That updated investigation shows revenue forecasts to 2025 at overall world market, submarket, product and national level. It forecasts six antibiotic classes:
Other medicines for treating bacterial infections.
Those analyses forecast the revenues of 43 leading antibacterial drugs from 2015 to 2025, including Zyvox, Cubicin, Augmentin, Zosyn/Tazocin, Avelox, Invanz and generic amoxcillin. The new survey also discusses antibacterial agents in clinical trials, examining research and development. That work assesses activities of companies including Pfizer, GSK, Novartis, Merck & Co., Cubist Pharmaceuticals and Bayer.
That report includes trends and forecast revenues in leading national markets. Countries and regions analysed are the US, the EU, Germany, France, the UK, Spain, Italy, Japan, Brazil, Russia, India, China and South Korea. That study also contains three interviews with other authorities on antimicrobial medicines.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : email@example.com
back to News